title: Orlando Magic: report from the 57th meeting of the American Society of Haematology, 5-7 December 2015, Orlando, USA.
abstract: The 57th American Society of Haematology (ASH) meeting held in Orlando, FL was certainly the year when myeloma management changed for good, with a plethora of newly Food and Drug Administration (FDA)-approved drugs showing impressive outcome improvements and the introduction of new techniques for disease monitoring. Also, chimeric antigen receptor (CAR) T cells continued their triumphal march, consolidating their success in lymphoma and chronic lymhocytic leukaemia (CLL) and venturing into new fields such as again multiple myeloma. Some experimental drugs showed long-awaited results (midostaurin in FLT3-mutated acute myeloid leukaemia (AML)) and some brand new drugs showed promising results in the clinic after extensive preclinical studies, such as those targeting new epigenetic factors (histone methyltransferases) and apoptosis.
authors.affiliation: European Institute of Oncology, Via Ripamonti 435, Milan 20141, Italy.
authors.forename: Luca
authors.initials: L
authors.lastname: Mazzarella
keywords: leukemia; lymphoma; myeloma
references.citation: N Engl J Med. 2016 Jan 28;374(4):311-22
references.pmid: 26639348
references.citation: N Engl J Med. 2015 Sep 10;373(11):1040-7
references.pmid: 26352815
references.citation: N Engl J Med. 2015 Dec 17;373(25):2425-37
references.pmid: 26639149
references.citation: Leukemia. 2006 Sep;20(9):1467-73
references.pmid: 16855634
references.citation: Lancet Oncol. 2014 Dec;15(13):1503-12
references.pmid: 25456369
references.citation: Nat Med. 2014 May;20(5):548-54
references.pmid: 24705333